Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

The rationale for a role for diet and nutrition in the prevention and treatment of cancer.

Logan J, Bourassa MW.

Eur J Cancer Prev. 2018 Jul;27(4):406-410. doi: 10.1097/CEJ.0000000000000427.

PMID:
29461280
2.

Activation of Nrf2 and Hypoxic Adaptive Response Contribute to Neuroprotection Elicited by Phenylhydroxamic Acid Selective HDAC6 Inhibitors.

Gaisina IN, Lee SH, Kaidery NA, Ben Aissa M, Ahuja M, Smirnova NN, Wakade S, Gaisin A, Bourassa MW, Ratan RR, Nikulin SV, Poloznikov AA, Thomas B, Thatcher GRJ, Gazaryan IG.

ACS Chem Neurosci. 2018 May 16;9(5):894-900. doi: 10.1021/acschemneuro.7b00435. Epub 2018 Jan 17.

PMID:
29338172
3.

Multisession anodal transcranial direct current stimulation induces motor cortex plasticity enhancement and motor learning generalization in an aging population.

Dumel G, Bourassa MÈ, Charlebois-Plante C, Desjardins M, Doyon J, Saint-Amour D, De Beaumont L.

Clin Neurophysiol. 2017 Nov 21. pii: S1388-2457(17)31151-3. doi: 10.1016/j.clinph.2017.10.041. [Epub ahead of print]

PMID:
29223355
4.

Evaluating and Extending the Ocean Wind Climate Data Record.

Wentz FJ, Ricciardulli L, Rodriguez E, Stiles BW, Bourassa MA, Long DG, Hoffman RN, Stoffelen A, Verhoef A, O'Neill LW, Farrar JT, Vandemark D, Fore AG, Hristova-Veleva SM, Turk FJ, Gaston R, Tyler D.

IEEE J Sel Top Appl Earth Obs Remote Sens. 2017 May;10(5):2165-2185. doi: 10.1109/JSTARS.2016.2643641. Epub 2017 May 23.

5.

Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models.

Karuppagounder SS, Alim I, Khim SJ, Bourassa MW, Sleiman SF, John R, Thinnes CC, Yeh TL, Demetriades M, Neitemeier S, Cruz D, Gazaryan I, Killilea DW, Morgenstern L, Xi G, Keep RF, Schallert T, Tappero RV, Zhong J, Cho S, Maxfield FR, Holman TR, Culmsee C, Fong GH, Su Y, Ming GL, Song H, Cave JW, Schofield CJ, Colbourne F, Coppola G, Ratan RR.

Sci Transl Med. 2016 Mar 2;8(328):328ra29. doi: 10.1126/scitranslmed.aac6008.

6.

Multisession Anodal tDCS Protocol Improves Motor System Function in an Aging Population.

Dumel G, Bourassa ME, Desjardins M, Voarino N, Charlebois-Plante C, Doyon J, De Beaumont L.

Neural Plast. 2016;2016:5961362. doi: 10.1155/2016/5961362. Epub 2016 Jan 10.

7.

Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health?

Bourassa MW, Alim I, Bultman SJ, Ratan RR.

Neurosci Lett. 2016 Jun 20;625:56-63. doi: 10.1016/j.neulet.2016.02.009. Epub 2016 Feb 8. Review.

8.

Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases.

Karuppagounder SS, Kumar A, Shao DS, Zille M, Bourassa MW, Caulfield JT, Alim I, Ratan RR.

Brain Res. 2015 Dec 2;1628(Pt B):273-287. doi: 10.1016/j.brainres.2015.07.030. Epub 2015 Jul 29. Review.

9.

Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism.

Olson DE, Sleiman SF, Bourassa MW, Wagner FF, Gale JP, Zhang YL, Ratan RR, Holson EB.

Chem Biol. 2015 Apr 23;22(4):439-445. doi: 10.1016/j.chembiol.2015.03.014. Epub 2015 Apr 16.

10.

Failure of temporal selectivity: Electrophysiological evidence for (mis)selection of distractors during the attentional blink.

Bourassa MÈ, Vachon F, Brisson B.

Psychophysiology. 2015 Jul;52(7):933-41. doi: 10.1111/psyp.12426. Epub 2015 Apr 9.

PMID:
25854745
11.

Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.

Sleiman SF, Olson DE, Bourassa MW, Karuppagounder SS, Zhang YL, Gale J, Wagner FF, Basso M, Coppola G, Pinto JT, Holson EB, Ratan RR.

J Neurosci. 2014 Oct 22;34(43):14328-37. doi: 10.1523/JNEUROSCI.1010-14.2014. Erratum in: J Neurosci. 2015 Jan 7;35(1):438.

12.

Electrophysiological correlates of motor sequence learning.

Beaulieu C, Bourassa MÈ, Brisson B, Jolicoeur P, De Beaumont L.

BMC Neurosci. 2014 Aug 28;15:102. doi: 10.1186/1471-2202-15-102.

13.

Metal-deficient aggregates and diminished copper found in cells expressing SOD1 mutations that cause ALS.

Bourassa MW, Brown HH, Borchelt DR, Vogt S, Miller LM.

Front Aging Neurosci. 2014 Jun 16;6:110. doi: 10.3389/fnagi.2014.00110. eCollection 2014.

14.

The interplay between microRNAs and histone deacetylases in neurological diseases.

Bourassa MW, Ratan RR.

Neurochem Int. 2014 Nov;77:33-9. doi: 10.1016/j.neuint.2014.03.012. Epub 2014 Mar 27. Review.

15.

Masking of a first target in the attentional blink attenuates the P3 to the first target and delays the P3 to the second target.

Brisson B, Bourassa MÈ.

Psychophysiology. 2014 Jul;51(7):611-9. doi: 10.1111/psyp.12204. Epub 2014 Mar 18.

PMID:
24635583
16.

Unravelling the structure of Magnus' pink salt.

Lucier BE, Johnston KE, Xu W, Hanson JC, Senanayake SD, Yao S, Bourassa MW, Srebro M, Autschbach J, Schurko RW.

J Am Chem Soc. 2014 Jan 29;136(4):1333-51. doi: 10.1021/ja4076277. Epub 2014 Jan 17.

PMID:
24437378
17.

Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration.

Bourassa MW, Leskovjan AC, Tappero RV, Farquhar ER, Colton CA, Van Nostrand WE, Miller LM.

Biomed Spectrosc Imaging. 2013 Apr 1;2(2):129-139.

18.

Dynamic full-field infrared imaging with multiple synchrotron beams.

Stavitski E, Smith RJ, Bourassa MW, Acerbo AS, Carr GL, Miller LM.

Anal Chem. 2013 Apr 2;85(7):3599-605. doi: 10.1021/ac3033849. Epub 2013 Mar 21.

19.

FTIR spectroscopic imaging of protein aggregation in living cells.

Miller LM, Bourassa MW, Smith RJ.

Biochim Biophys Acta. 2013 Oct;1828(10):2339-46. doi: 10.1016/j.bbamem.2013.01.014. Epub 2013 Jan 25. Review.

20.

Metal imaging in neurodegenerative diseases.

Bourassa MW, Miller LM.

Metallomics. 2012 Aug;4(8):721-38. doi: 10.1039/c2mt20052j. Epub 2012 Jul 16. Review.

21.

Patients with coronary artery disease unsuitable for revascularization: definition, general principles, and a classification.

Jolicoeur EM, Cartier R, Henry TD, Barsness GW, Bourassa MG, McGillion M, L'Allier PL.

Can J Cardiol. 2012 Mar-Apr;28(2 Suppl):S50-9. doi: 10.1016/j.cjca.2011.10.015. Review.

PMID:
22424284
22.

Heart rate recovery after exercise and long-term prognosis in patients with coronary artery disease.

Gayda M, Bourassa MG, Tardif JC, Fortier A, Juneau M, Nigam A.

Can J Cardiol. 2012 Mar-Apr;28(2):201-7. doi: 10.1016/j.cjca.2011.12.004. Epub 2012 Feb 14.

PMID:
22336522
23.

An early proof-of-concept of cardiac resynchronization therapy.

Bourassa MG, Khairy P, Roy D.

World J Cardiol. 2011 Dec 26;3(12):374-6. doi: 10.4330/wjc.v3.i12.374.

24.

Effects of fasting and/or postprandial glucose on heart rate recovery in patients with coronary heart disease.

Gayda M, Bourassa MG, Tardif JC, Fortier A, Juneau M, Nigam A.

Diabetes Metab. 2012 Feb;38(1):20-6. doi: 10.1016/j.diabet.2011.06.004. Epub 2011 Aug 24.

PMID:
21868273
25.

Update on distance and velocity requirements for community ambulation.

Andrews AW, Chinworth SA, Bourassa M, Garvin M, Benton D, Tanner S.

J Geriatr Phys Ther. 2010 Jul-Sep;33(3):128-34.

PMID:
21155508
26.

Copper and zinc metallation status of copper-zinc superoxide dismutase from amyotrophic lateral sclerosis transgenic mice.

Lelie HL, Liba A, Bourassa MW, Chattopadhyay M, Chan PK, Gralla EB, Miller LM, Borchelt DR, Valentine JS, Whitelegge JP.

J Biol Chem. 2011 Jan 28;286(4):2795-806. doi: 10.1074/jbc.M110.186999. Epub 2010 Nov 10.

27.

Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial.

Rana JS, Hardison RM, Pop-Busui R, Brooks MM, Jones TL, Nesto RW, Bourassa MG; BARI 2D Investigators.

Prev Cardiol. 2010 Summer;13(3):112-6. doi: 10.1111/j.1751-7141.2010.00067.x.

28.

Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations.

Solymoss BC, Bourassa MG, Marcil M, Levesque S, Varga S, Campeau L.

Coron Artery Dis. 2009 Jan;20(1):1-8. doi: 10.1097/MCA.0b013e32831624a5.

PMID:
19050599
29.

Genetic Diversity in Poplar Leaf Rust (Melampsora medusae f. sp. deltoidae) in the Zones of Host Sympatry and Allopatry.

Bourassa M, Bernier L, Hamelin RC.

Phytopathology. 2007 May;97(5):603-10. doi: 10.1094/PHYTO-97-5-0603.

30.

Usefulness of self-reported leisure-time physical activity to predict long-term survival in patients with coronary heart disease.

Apullan FJ, Bourassa MG, Tardif JC, Fortier A, Gayda M, Nigam A.

Am J Cardiol. 2008 Aug 15;102(4):375-9. doi: 10.1016/j.amjcard.2008.03.072. Epub 2008 May 22.

PMID:
18678290
31.

Rhythm control versus rate control for atrial fibrillation and heart failure.

Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators.

N Engl J Med. 2008 Jun 19;358(25):2667-77. doi: 10.1056/NEJMoa0708789.

32.

Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.

Bourassa MG, Berry C.

Curr Atheroscler Rep. 2008 Apr;10(2):106-16.

PMID:
18417064
34.

Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease.

Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC.

Can J Cardiol. 2007 Sep;23(11):873-8.

35.

Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization.

Berry C, Tardif JC, Bourassa MG.

J Am Coll Cardiol. 2007 Feb 13;49(6):643-56. Epub 2007 Jan 26. Review.

36.

Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.

Berry C, Tardif JC, Bourassa MG.

J Am Coll Cardiol. 2007 Feb 13;49(6):631-42. Epub 2007 Jan 26. Review.

37.
38.

Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction.

De Denus S, White M, Tardif JC, Bourassa MG, Racine N, Levesque S, Ducharme A.

J Card Fail. 2006 Jun;12(5):353-9.

PMID:
16762798
39.

What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial.

Eisenstein EL, Yusuf S, Bindal V, Bourassa MG, Horney A, Collins JF, Mark DB; DIG investigators.

J Card Fail. 2006 Jun;12(5):336-42.

PMID:
16762794
40.

The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease.

Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC.

Am Heart J. 2006 Feb;151(2):514-21.

PMID:
16442923
41.

The history of cardiac catheterization.

Bourassa MG.

Can J Cardiol. 2005 Oct;21(12):1011-4.

PMID:
16234881
42.

Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.

Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators.

Eur Heart J. 2005 Dec;26(23):2529-36. Epub 2005 Oct 7.

PMID:
16214830
43.

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease.

Diaz A, Bourassa MG, Guertin MC, Tardif JC.

Eur Heart J. 2005 May;26(10):967-74. Epub 2005 Mar 17.

PMID:
15774493
44.

Angiotensin II inhibition and prevention of atrial fibrillation and stroke.

Bourassa MG.

J Am Coll Cardiol. 2005 Mar 1;45(5):720-1. No abstract available.

45.

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.

Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators.

Lancet. 2004 Sep 4-10;364(9437):849-57.

PMID:
15351192
46.

Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI).

Alderman EL, Kip KE, Whitlow PL, Bashore T, Fortin D, Bourassa MG, Lesperance J, Schwartz L, Stadius M; Bypass Angioplasty Revascularization Investigation.

J Am Coll Cardiol. 2004 Aug 18;44(4):766-74.

47.

Classification and risk stratification of patients with acute chest pain using a low discriminatory level of cardiac troponin T.

Solymoss BC, Bourassa MG, Cernacek P, Fortier A, Théroux P.

Clin Cardiol. 2004 Mar;27(3):130-6.

48.
49.

Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity.

Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lespérance J, Lévesque S, Varga S.

Am J Cardiol. 2004 Jan 15;93(2):159-64.

PMID:
14715340
50.

Incidence, coronary risk profile and angiographic characteristics of prediabetic and diabetic patients in a population with ischemic heart disease.

Solymoss BC, Bourassa MG, Campeau L, Lespérance J, Marcil M, Varga S.

Can J Cardiol. 2003 Sep;19(10):1155-60.

PMID:
14532941

Supplemental Content

Loading ...
Support Center